Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC)

Lung Cancer

Volumn 69, Issue SUPPL. 1, 2010, Pages

  Stanisic, Sanja ^a   Bischoff, Helge G ^b   Heigener, David F ^c   Vergnenègre, Alain ^d   de Castro Carpeño, Javier ^e   Chouaid, Christos ^f   Walzer, Stefan ^g   Mueller, Elvira ^a   Schmidt, Elvira ^a  

^a Analytica International   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c KRANKENHAUS GROSSHANSDORF   (Germany)

^d Hopital du Cluzeau   (France)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f HÔPITAL SAINT ANTOINE   (France)

^g F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Bevacizumab; Cost; Cost savings; Indirect cost; NSCLC; Productivity

Indexed keywords

BEVACIZUMAB; CARBOPLATIN;

AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMIC ASPECT; EMPLOYMENT STATUS; HEALTH STATUS; HUMAN; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT DURATION; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COST OF ILLNESS; DEOXYCYTIDINE; EUROPEAN UNION; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; PACLITAXEL;

EID: 77956032980     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(10)70135-5     Document Type: Article

References (25)

1. Ferlay J, Bray F, Pisani P GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5 version 2.0 2004, International Agency for Research in Cancer (IARC) Press, Lyon, France.
2. Loddenkemper R The burden of lung cancer in Europe. European Respiratory Disease [Internet]. 2006 [cited 2010 Jun 10] http://www.touchrespiratory.com/files/article_pdfs/resp_6154.
3. Weißflog D, Matthys H, Hasse J, Virchow JC Epidemiologie und Kosten des Bronchialkarzinoms in Deutschland. Pneumologie 2001, 55(7):333-338.
4. American Cancer Society Cancer Facts & Figures 2009 2009, American Cancer Society.
5. Yang P, Allen MS, Aubry MC, Wampfler JA, Marks RS, Edell ES, et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 2005, 128(1):452-462.
6. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346(2):92-98.
7. EMEA. European Public Assessment Report (EPAR) summary for the public Avastin. European Medicines Agency [Internet]. 2010 [cited 2010 Jul 6].
8. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009, 27(8):1227-1234.
9. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355(24):2542-2550.
10. Sandler A, Yi J, Hambleton J, Kolb M, Johnson D. Treatment outcomes by tumor histology in Eastern Cooperative Group (ECOG) study E4599 of bevacizumab (BV) with paclitaxel/carboplatin (PC) for advanced non-small cell lung cancer (NSCLC). Chicago Multidisciplinary Symposium in Thoracic Oncology, November 13 15, 2008.
11. Organisation for Economic Co-operation and Development OECD Glossary of Statistical Terms 2007, OECD, Paris.
12. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010, [Epub ahead of print].
13. F. Hoffmann-La Roche Pharmaceuticals AG. A study of avastin (bevacizumab) in patients with non-squamous non-small cell lung cancer (NSCLC) Avastin in Lung Cancer (AVAiL) trial. Data on file.
14. F. Hoffmann-La Roche Pharmaceuticals AG. Combination chemo-therapy with or without bevacizumab in treating patients with advanced, metastatic, or recurrent non-small cell lung cancer E4599 trial. Data on file.
15. EUROSTAT Eurostat Tables, Graphs and Maps Interface Employment rate by gender. EUROSTAT [Internet]. 2010 [cited 2009 Dec 15] http://epp.eurostat.ec.europa.eu/tgm/table.do?tab=table&init=1&plugin=1&language=en&pcode=tsiem010.
16. EUROSTAT Eurostat Tables, Graphs and Maps Interface (TGM) table Monthly Labor Costs. EUROSTAT [Internet]. 2010 [cited 2009 Dec 15] http://epp.eurostat.ec.europa.eu/tgm/table.do?tab=table&init=1&plugin=1&language=en&pcode=tps001742.
17. EUROSTAT Eurostat Tables, Graphs and Maps Interfaces Annual average rate of change in Harmonized Indices of Consumer Prices (HICPs). EUROSTAT [Internet]. 2010 [cited 2009 Dec 15] http://epp.eurostat.ec.europa.eu/tgm/table.do?tab=table&init=1&plugin=1&language=en&pcode=tsieb060.
18. Institut National du Cancer Analyse Économique des Coûuts du Cancer en France: Impact sur la qualié de la vie, prévention, dépistage, soins, recherche. 52, avenue André-Morizet, 92513 Boulogne-Billancourt: Institut National du Cancer, 2007 http://www.e-cancer.fr/presse/dossiers-kits-et-communiques-de-presse-2010-2009/589-non-categorise-presse/1546.
19. Tan A, Freeman DH, Freeman JL, Zhang DD, Dayal H, Philips BU. The cost of cancer in Texas, 2007. Texas Cancer Registry, Texas Department of Health Care Service, Publication No. 10-13121, 2009.
20. Romanus D, Neumman P, Earle C, Weinstein MC, Weeks JC, Farber D The impact of initial treatment choice and disease progression on the economic burden of patients and their caregivers a longitudinal study of stage IV non small cell lung cancer (NSCLC) [abstract]. Value in Health 2008, 11(6):A482.
21. Gridelli C, Ferrara C, Guerriero C, Palazzo S, Grasso G, Pavese I, et al. Informal caregiving burden in advanced non-small cell lung cancer: the HABIT study. J Thorac Oncol 2007, 2(6):475-480.
22. Jacoulet P, Depierre A, Moro D, Rivière A, Milleron B, Quoix E, et al. Long-term survivors of small-cell lung cancer (SCLC): a French multicenter study. Groupe d'Oncologie de Langue Française. Ann Oncol 1997, 8(10):1009-1014.
23. Bradley CJ, Bednarek HL Employment patterns of long-term cancer survivors. Psychooncology 2002, 11(3):188-198.
24. Taskila-Åbrandt T, Martikainen R, Virtanen SV, Pukkala E, Hietanen P, Lindbohm M-L The impact of education and occupation on the employment status of cancer survivors. Eur J Cancer 2004, 40(16):2488-2493.
25. Dansin E, Tsai CM, Pavlakis N, Laskin J, Griesinger F, Garrido P, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-small cell lung cancer [abstract]. EJC Suppl 2009, 7(2):556.